The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
56 / 72
Overall Ranking
319 / 4737
Industry
Chemicals
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+100.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company has two product lines of fertility control products: ContraPest and Evolve. Its product ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions of the rat population. ContraPest is a highly palatable liquid formulation that reduces fertility in both male and female rats. Additionally, ContraPest does not cause illness in rats, and, therefore, it does not change behavior or result in bait aversion. ContraPest offers a new tool used in coordination with rodenticides as part of an integrated pest management program. The Company's technology can also be applied to other mammalian species.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 82.24% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.86M.
Overvalued
The company’s latest PE is 0.09, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 110.88K shares, decreasing 33.84% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 13.50K shares of this stock.
SenesTech, Inc. develops and commercializes products for managing animal pest populations, initially rat populations, through fertility control. The Company has two product lines of fertility control products: ContraPest and Evolve. Its product ContraPest, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide (VCD) and triptolide. ContraPest targets the reproductive systems of both male and female Norway and roof rats beginning with the first breeding cycle following consumption, which can lead to sustained reductions of the rat population. ContraPest is a highly palatable liquid formulation that reduces fertility in both male and female rats. Additionally, ContraPest does not cause illness in rats, and, therefore, it does not change behavior or result in bait aversion. ContraPest offers a new tool used in coordination with rodenticides as part of an integrated pest management program. The Company's technology can also be applied to other mammalian species.